Tarlatamab: Mechanism of Action and Clinical Success in Small Cell Lung Cancer │ Pharmacology

Clinical Trial: Tarlatamab for Small Cell Lung Cancer (NCT04885998)Подробнее

Tarlatamab Mechanism of ActionПодробнее

IMDELLTRA™ (tarlatamab-dlle)- extensive stage small cell lung cancerПодробнее

Evaluating Tarlatamab in Recurrent Small Cell Lung Cancer TreatmentПодробнее

Small Cell Lung Cancer (SCLC) Algorithm - Drs. Rohit & Rahul Gosain with Dr. Estelamari RodriguezПодробнее

Understanding Immunotherapy for Lung CancerПодробнее

Osimertinib in Advanced Non–Small-Cell Lung CancerПодробнее

Pharmacology - Cancer Oncology drugs Nursing RN PN Full Video (MADE EASY)Подробнее

The DLL3-targeting BiTE, tarlatamab, for the treatment of SCLCПодробнее

Charles’s Journey with Small Cell Lung CancerПодробнее

Exploring antibody-drug conjugates (ADCs) in lung cancerПодробнее

Activated T cell attacks a cancer cellПодробнее

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJMПодробнее

Lurbinectedin Mechanisim of ActionПодробнее

Immunotherapy Activates the Immune SystemПодробнее

Antibodies against Non Small Cell Lung Cancer (ALK)Подробнее

S3 Episode 5: Revolutionizing Small Cell Lung Cancer: A Deep Dive into Immunotherapy Advancements...Подробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaПодробнее